Vantage Point

Share this article:
Merck recently announced it is forming a new division, Merck BioVentures MBV, to make copycat versions of biotech drugs. In its immediate target zone are products such as Amgen's Aranesp, a long-acting treatment for anemia that Merck expects to launch in 2012.

This announcement is of interest to healthcare marketing researchers for two major reasons.  First, while the distinction between branded and generic products has for many years been black and white, the notion of a copycat biotech product, which is similar but not identical to the original, establishes a gray zone that will elicit opinions and procedures from stakeholders, including physicians, patients and payers. We will need to keep up with these perspectives and practices, which could reshape biotech.

Second, and probably of greater interest, this move supports a strategic direction by several historically branded pharma companies of taking major stakes in the generic space. In the near future, as several observers have noted, the distinction between branded and generic pharma companies will break down, with significant impact on healthcare, the industry and the marketing research we conduct. The Obama administration, with its intention of making it easier for companies to get generics approved, will further support this trend.  

The nature of the businesses we serve will change, from a world cleanly divided into brand name vs. generics into one where the division is far less clear. The issues we research will be more about science, business strategy and tactics and pricing, and less about the promotional efforts to which so much attention has historically been paid in the “marketing” of pharma products.

Richard Vanderveer is CEO of GfK Healthcare 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Vantage Point

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Vantage Point

Vantage Point: Payers—the "experts" in healthcare research

Vantage Point: Payers—the "experts" in healthcare research

Access to payers is about knowledge, about understanding what they do in their jobs

Vantage Point: Determining "fair market value"

Vantage Point: Determining "fair market value"

Should pharma formulate a super matrix to determine the FMV of research incentives?

Vantage Point: Marketing Support for Clinical Trials

Vantage Point: Marketing Support for Clinical Trials

Pharmaceutical companies must provide robust marketing support for their clinical trials